Halozyme Therapeutics Inc (HALO) Stock Price, Quote, News & History

HALONASDAQ
$78.60
1.511.96%
At close: Jul 20, 5:00 PM EST
$79.33
2.242.91%
Pre-Market: 8:31 AM EST
40%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
677.42M
Investing Cash Flow (TTM)
-458.27M
Financing Cash Flow (TTM)
-83.47M
Free Cash Flow (TTM)
379.88M
Capital Expenditure (TTM)
-297.53M
Net Change in Cash (TTM)
135.68M

Analyst Trends and Forecast

1
1
Feb
1
Apr
1
May
1
Jul
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.2
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$11.15B
PE Ratio (TTM)
27.58
PE Ratio (FWD)
10.88
PEG Ratio (TTM)
-
PS Ratio (TTM)
6.41
PB Ratio (TTM)
42.45
Earnings Yield % (TTM)
3.63%
Earnings Yield % (FWD)
9.19%
EV / EBITDA (TTM)
17.87
Price / EBITDA (TTM)
15.49
Price / Free Cash Flow (TTM)
25.44
Book Value / Share
$1.85

Company Debt

Total Debt
$2.14B
LT Debt
$1.94B
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$309.75M
Debt to Equity
9.76
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
-
Close
$78.60
Volume / Avg.
5.00 / 1.80M
Day Range
- - -
52 Wk Range
55.64 - 82.26
Market Cap
$9.41B
P/E Ratio
27.58
Dividend Yield
-
Exchange
NASDAQ
RSI
65
Short Interest
14.42%
Days to Cover
6.27

About

Sector
Health Care
Industry
Biotechnology
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary ...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Halozyme Therapeutics (HALO) stock?

A

You can purchase shares of Halozyme Therapeutics (NASDAQ:HALO) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Halozyme Therapeutics (HALO) competitors?

A

There are no as such competitors for Halozyme Therapeutics.

Q

What is the forecast, or price target, for Halozyme Therapeutics (HALO) stock?

A

Halozyme Therapeutics has a consensus price target of $75.47.

Q

What is the current price for Halozyme Therapeutics (HALO)?

A

The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $79.3324 last updated July 21, 2026 at 6:33 PM EDT.

Q

Does Halozyme Therapeutics (HALO) pay a dividend?

A

There are no upcoming dividends for Halozyme Therapeutics.

Q

When is Halozyme Therapeutics (NASDAQ:HALO) reporting earnings?

A

Halozyme Therapeutics does not have any upcoming earnings scheduled.

Q

Is Halozyme Therapeutics (HALO) going to split?

A

There is no upcoming split for Halozyme Therapeutics.

Q

What sector and industry does Halozyme Therapeutics (HALO) operate in?

A

Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.